Q-omics provides the consensus-scored GATAD2A profile across patient tissues and cancer cell-line models. GATAD2A expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, GATAD2A is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, GATAD2A protein abundance shows 22,663 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SCLC, HNSC, and GBM as cancer lineages where GATAD2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GATAD2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GATAD2A survival associations across molecular data types. GATAD2A RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GATAD2A RNA expression–survival associations across cancer types. High GATAD2A expression shows unfavorable associations in MESO, ACC, BLCA, LGG and SKCM, but favorable associations in SCLC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for GATAD2A RNA expression.
This table summarizes GATAD2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GATAD2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GATAD2A shows higher tumor expression in HNSC, BLCA, KIRC, COAD, LIHC and STAD. The HNSC box plot shows higher GATAD2A RNA expression in tumor versus normal tissue (log2 FC = +1.088, t-test p < 0.001).
This table shows molecular features associated with GATAD2A in patient tissues and cancer cell lines. In patient samples, GATAD2A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GATAD2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
